Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

Published:2020-11-20 Issue:2 Volume:39 Page:267-269
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Innocenti Idanna¹,Sora Federica¹²,Autore Francesco¹^ORCID,Chiusolo Patrizia¹²,Giammarco Sabrina¹,Metafuni Elisabetta¹^ORCID,Bacigalupo Andrea¹²,Sica Simona¹²,Laurenti Luca¹²^ORCID

Affiliation:

1. Dipartimento di Diagnostica per Immagini Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS Roma Italy

2. Dipartimento di Scienze Radiologiche ed Ematologiche Sezione di Ematologia Università Cattolica del Sacro Cuore Roma Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2826

Reference12 articles.

1. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

2. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

3. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

4. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

5. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation;Annals of Hematology;2021-07-08